CAJ | 학술논문

目的：探讨胃癌术后患者核苷酸切除修复交叉互补基因1（ERCC1）、胸苷酸合成酶（ TS）表达与术后辅助化疗预后的关系。方法选取86例初次诊断为胃癌行胃癌根治术、术后病理诊断为Ⅱ～Ⅲ期的患者，术后均采用XELOX辅助化疗方案化疗，并进行4年以上随访。运用免疫组化方法检测患者癌组织中ERCC1、 TS蛋白表达情况，分析ERCC1、TS表达与术后辅助化疗预后的关系。结果86例胃癌患者癌组织中ERCC1和TS的阳性表达率分别为40％和36％。 ERCC1和TS阳性表达率与肿瘤的分化程度相关。 ERCC1阴性表达者和TS阴性表达者平均生存期均明显长于阳性表达者（ P均＜0．05）。多因素COX回归分析表明，ERCC1、TS阳性表达者术后辅助化疗预后差[HR＝0．29，95％CI（0．12，0．69），P ＝0．006；HR＝0．49，95％CI（0．20，0．87），P＝0．010]。结论 ERCC1与TS表达情况可以作为预测胃癌术后辅助化疗预后的分子标志物。
목적：탐토위암술후환자핵감산절제수복교차호보기인1（ERCC1）、흉감산합성매（ TS）표체여술후보조화료예후적관계。방법선취86례초차진단위위암행위암근치술、술후병리진단위Ⅱ～Ⅲ기적환자，술후균채용XELOX보조화료방안화료，병진행4년이상수방。운용면역조화방법검측환자암조직중ERCC1、 TS단백표체정황，분석ERCC1、TS표체여술후보조화료예후적관계。결과86례위암환자암조직중ERCC1화TS적양성표체솔분별위40％화36％。 ERCC1화TS양성표체솔여종류적분화정도상관。 ERCC1음성표체자화TS음성표체자평균생존기균명현장우양성표체자（ P균＜0．05）。다인소COX회귀분석표명，ERCC1、TS양성표체자술후보조화료예후차[HR＝0．29，95％CI（0．12，0．69），P ＝0．006；HR＝0．49，95％CI（0．20，0．87），P＝0．010]。결론 ERCC1여TS표체정황가이작위예측위암술후보조화료예후적분자표지물。
Abstrac t:Objective It is to investigate the relationship of the expression of ERCC1 and TS in gastric cancer with the prognosis after postoperative adjuvant chemotherapy.Methods 86 patients who were diagnosed gastric cancer for the first time were enrolled in our study.All the patients were received radical operation, pathologic diagnosis stage wasⅡorⅢstage, and all accepted XELOX chemotherapy and followed at least 4 years.The expressions of ERCC1 and TS in gastric cancer tissue were detected by Immunohistochemistry method.The relationship of the expression of ERCC1 and TS with the prognosis was analyzed.Results The positive expression rate of ERCC1 and TS in 86 cases was 40%and 36%respectively.There were neg-ative correlation between the positive expression of ERCC1 and TS and the differentiation of tumor.The mean survival time of patients with negative expression of ERCC1 and TS were significant longer than those with positive expression ( all P<0.05) . COX multivariate regression analysis revealed that patients with ERCC1 and TS didn't benefit from chemotherapy [HR=0.29, 95%CI(0.12,0.69), P=0.006;HR=0.49, 95%CI(0.20, 0.87), P=0.010].Conclusion ERCC1 and TS may be a biomarker to predict the prognosis of gastric cancer patients receiving chemotherapy.